Research on cachexia, sarcopenia and skeletal muscle in cardiology

Journal of Cachexia, Sarcopenia and Muscle

Volumn 3, Issue 4, 2012, Pages 219-223

  Coats, Andrew J S ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Cachexia; Cardiology; Obesity; Sarcopenia; Skeletal muscle; Wasting disorders

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GHRELIN; INTERCELLULAR ADHESION MOLECULE 1; LEPTIN; PIOGLITAZONE;

ACUTE HEART INFARCTION; ANEMIA; APPETITE; BODY FAT; BODY MASS; CACHEXIA; CARDIOVASCULAR DISEASE; ECG ABNORMALITY; ENDOTHELIAL DYSFUNCTION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; INFLAMMATION; KINESIOTHERAPY; MEDICAL LITERATURE; MEDICAL RESEARCH; MUSCLE ATROPHY; MUSCLE WEAKNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITIONAL ASSESSMENT; NUTRITIONAL DEFICIENCY; NUTRITIONAL SUPPORT; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REHABILITATION CARE; REVIEW; RISK FACTOR; SARCOPENIA; SKELETAL MUSCLE; SURVIVAL; TRANSLUMINAL CORONARY ANGIOPLASTY; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

EID: 84879112021     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-012-0090-6     Document Type: Review

References (66)

1. Marinou K, Tousoulis D, Antonopoulos AS, Stefanadi E, Stefanadis C. Obesity and cardiovascular disease: from pathophysiology to risk stratification. Int J Cardiol. 2010;138: 3-8.
2. Thompson AM, Zhang Y, Tong W, et al. Association of obesity and biomarkers of inflammation and endothelial dysfunction in adults in Inner Mongolia, China. Int J Cardiol. 2011;150: 247-52.
3. Younge JO, Damen NL, van Domburg RT, Pedersen SS. Obesity, health status, and 7-year mortality in percutaneous coronary intervention: in search of an explanation for the obesity paradox. Int J Cardiol. 2012. doi: 10. 1016/j. ijcard. 2012. 03. 105.
4. Trullàs JC, Formiga F, Montero M, the RICA Investigators, et al. Impact of weight loss on mortality in chronic heart failure: findings from the RICA Registry. Int J Cardiol. 2012. doi: 10. 1016/j. ijcard. 2012. 09. 062.
5. Zamora E, Lupón J, de Antonio M, et al. The obesity paradox in heart failure: is etiology a key factor? Int J Cardiol. 2011. doi: 10. 1016/j. ijcard. 2011. 11. 022.
6. Tepsuwan T, Schuarattanapong S, Woragidpoonpol S, et al. Incidence and impact of cardiac cachexia in valvular surgery. Geol Geofiz. 2009;17: 617-21.
7. Clark AL, Anker SD. Body mass, chronic heart failure, surgery and survival. J Heart Lung Transplant. 2010;29: 261-4.
8. Ege MR, Altay H. The impact of body mass index on clinical outcomes after acute myocardial infarction. Int J Cardiol. 2010;145: 539.
9. Aronson D, Nassar M, Goldberg T, Kapeliovich M, Hammerman H, Azzam ZS. The impact of body mass index on clinical outcomes after acute myocardial infarction. Int J Cardiol. 2010;145: 476-80.
10. Long MJ, Jiang CQ, Lam TH, Xu L, Zhang WS, Lin JM, Ou JP, Cheng KK. Atrial fibrillation and obesity among older Chinese: the Guangzhou Biobank Cohort Study. Int J Cardiol. 2011;148: 48-52.
11. Doehner W, Erdmann E, Cairns R, Clark AL, Dormandy JA, Ferrannini E, Anker SD. Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. Int J Cardiol. 2011. doi: 10. 1016/j. ijcard. 2011. 09. 03.
12. Zavin A, Daniels K, Arena R, Allsup K, Lazzari A, Joseph J, Schulze PC, Lecker SH, Forman DE. Adiposity facilitates increased strength capacity in heart failure patients with reduced ejection fraction. Int J Cardiol. 2012. doi: 10. 1016/j. ijcard. 2012. 06. 00.
13. de Simone G, Pasanisi F, Ferrara AL, Roman MJ, Lee ET, Contaldo F, Howard BV, Devereux RB. Relative fat-free mass deficiency and left ventricular adaptation to obesity: The Strong Heart Study. Int J Cardiol. 2012. doi: 10. 1016/j. ijcard. 2012. 09. 055.
14. Piepoli MF, Guazzi M, Boriani G, et al. Exercise intolerance in chronic heart failure: mechanisms and therapies. Part II. Eur J Cardiovasc Prev Rehabil. 2010;17: 643-8.
15. Toth MJ, Shaw AO, Miller MS, VanBuren P, LeWinter MM, Maughan DW, et al. Reduced knee extensor function in heart failure is not explained by inactivity. Int J Cardiol. 2010;143: 276-82. Epub 2009 Mar 27.
16. Georgiadou P, Adamopoulos S. Skeletal muscle abnormalities in chronic heart failure. Curr Heart Fail Rep. 2012;9: 128-32.
17. Bing C. Lipid mobilization in cachexia: mechanisms and mediators. Curr Opin Support Pall Care. 2011;5: 356-60.
18. Fearon KC. Cancer cachexia and fat-muscle physiology. N Engl J Med. 2011;365: 565-7.
19. Filusch A, Ewert R, Altesellmeier M, Zugck C, Hetzer R, Borst MM, Katus HA, Meyer FJ. Respiratory muscle dysfunction in congestive heart failure-the role of pulmonary hypertension. Int J Cardiol. 2011;150: 182-5.
20. Lourenço AP, Fontoura D, Henriques-Coelho T, Leite-Moreira AF. Current pathophysiological concepts and management of pulmonary hypertension. Int J Cardiol. 2012;155: 350-61.
21. Tian M, Asp ML, Nishijima Y, Belury MA. Evidence for cardiac atrophic remodeling in cancer-induced cachexia in mice. Int J Oncol. 2011;39: 1321-6.
22. Tian M, Nishijima Y, Asp ML, Stout MB, Reiser PJ, Belury MA. Cardiac alterations in cancer-induced cachexia in mice. Int J Oncol. 2010;37: 347-53.
23. Zastrow A, Wolf J, Giannitsis E, Katus H, Herzog W, Friederich HC, Mussler C. Elevated myocardial enzymes and natriuretic peptides in anorexia nervosa: prototypic condition for the pathophysiology of cachexia? Cardiology. 2011;118: 256-9.
24. Araújo JP, Lourenço P, Rocha-Gonçalves F, Ferreira A, Bettencourt P. Nutritional markers and prognosis in cardiac cachexia. Int J Cardiol. 2011;146: 359-63.
25. Amarelli C, Buonocore M, Romano G, Maiello C, De Santo LS. Nutritional issues in heart transplant candidates and recipients. Front Biosci. 2012;4: 662-8.
26. Anker SD, Laviano A, Filippatos G, et al. ESPEN Guidelines on Parenteral Nutrition: on cardiology and pneumology. Clin Nutr. 2009;28: 455-60.
27. Celi{dotless}k T, Yuksel UC. The small intestine in cardiac cachexia: a forgotten player of the game. Int J Cardiol. 201;147: 186-7.
28. Sandek A, Valentova M, von Haehling S, Doehner W, Anker SD. The small intestine: a critical linkage in pathophysiology of cardiac cachexia. Int J Cardiol. 2011;146: 277-8.
29. Celik T, Iyisoy A, Yuksel UC, Jata B. The small intestine: a critical linkage in pathophysiology of cardiac cachexia. Int J Cardiol. 2010;143: 200-1.
30. Attanasio P, Anker SD, Doehner W, von Haehling S. Hormonal consequences and prognosis of chronic heart failure. Curr Opin Endocrinol Diabet Obes. 2011;18: 224-30.
31. Vaz Pérez A, Doehner W, von Haehling S, Schmidt H, Zimmermann AV, Volk HD, Anker SD, Rauchhaus M. he relationship between tumor necrosis factor-α, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure. Int J Cardiol. 2010;141: 39-43.
32. Chauhan A, Sequeria A, Manderson C, Maddocks M, Wasley D, Wilcock A. Exploring autonomic nervous system dysfunction in patients with cancer cachexia: a pilot study. Auton Neurosci-Bas Clin. 2012;166: 93-5.
33. Hagenah GC, Luers C, Prager D, Blaschke S. Association of Cheyne-Stokes respiration and cardiac cachexia in congestive heart failure. Int J Cardiol. 2010;142: 298-300.
34. Yoshida T, Semprun-Prieto L, Wainford RD, Sukhanov S, Kapusta DR, Delafontaine P. Angiotensin II, reduces food intake by altering orexigenic neuropeptide expression in the mouse hypothalamus. Endocrinology. 2012;153: 1411-20.
35. Breit SN, Johnen H, Cook AD, Tsai VW, Mohammad MG, Kuffner T, Zhang HP, Marquis CP, Jiang L, Lockwood G, Lee-Ng M, Husaini Y, Wu L, Hamilton JA, Brown DA. The TGF-beta superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors. 2011;29: 187-95.
36. Singh M, Bedi US, Singh PP, Arora R, Khosla S. Leptin and the clinical cardiovascular risk. Int J Cardiol. 2010;140: 266-71.
37. Araujo JP, Lourenco P, Rocha-Goncalves F, Ferreira A, Bettencourt P. Adiponectin is increased in cardiac cachexia irrespective of body mass index. Eur J Hear Fail. 2009;11: 567-72.
38. Tedeschi S, Pilotti E, Parenti E, et al. Serum adipokine zinc alpha2-glycoprotein and lipolysis in cachectic and noncachectic heart failure patients: relationship with neurohormonal and inflammatory biomarkers. Metab Clin Exp. 2012;61: 37-42.
39. Celik T, Yaman H. Elevated adiponectin levels in patients with chronic heart failure: an independent predictor of mortality or a marker of cardiac cachexia? Int J Cardiol. 2010;144: 319-20.
40. Szabo T, von Haehling S, Habedank D, Rauchhaus M, Lainscak M, Sandek A, Schefold J, Anker SD, Doehner W. Usefulness of minimal modelling to assess impaired insulin sensitivity in patients with chronic heart failure. Int J Cardiol. 2011;147: 47-51.
41. Dalla Libera L, Ravara B, Gobbo V, Betto DD, Germinario E, Angelini A, Evangelista S, Vescovo G. Skeletal muscle proteins oxidation in chronic right heart failure in rats: can different beta-blockers prevent it to the same degree? Int J Cardiol. 2010;143: 192-9.
42. Maccio A, Madeddu C, Gramignano G, et al. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol. 2012;124: 417-25.
43. Penet MF, Winnard Jr PT, Jacobs MA, Bhujwalla ZM. Understanding cancer-induced cachexia: imaging the flame and its fuel. Curr Opin Support Pall Care. 2011;5: 327-33.
44. Oreopoulos A, Kalantar-Zadeh K, McAlister FA, et al. Comparison of direct body composition assessment methods in patients with chronic heart failure. J Card Fail. 2010;16: 867-72.
45. Halliday V, Porock D, Arthur A, Manderson C, Wilcock A. Development and testing of a cancer appetite and symptom questionnaire. J Hum Nutr Diet. 2012;25: 217-24.
46. Blum D, Strasser F. Cachexia assessment tools. Curr Opin Support Pall Care. 2011;5: 350-5.
47. von Haehling S, Stepney R. Anker SD Advances in understanding and treating cardiac cachexia: highlights from the 5th Cachexia Conference. Int J Cardiol. 2010;144: 347-9.
48. Watkins F, Tulloch S, Bennett C, Webster B, McCarthy C. A multimodal, interdisciplinary programme for the management of cachexia and fatigue. Int J Palliat Nurs. 2012;18: 85-90.
49. Maddocks M, Murton AJ, Wilcock A. Improving muscle mass and function in cachexia: non-drug approaches. Curr Opin Support Pall Care. 2011;5: 361-4.
50. Lourenco AP, Vasques-Novoa F, Fontoura D, Bras-Silva C, Roncon-Albuquerque Jr R, Leite-Moreira AF. A Western-type diet attenuates pulmonary hypertension with heart failure and cardiac cachexia in rats. J Nutr. 2011;141: 1954-60.
51. Timmerman KL, Rasmussen BB. Does a reduction in anabolic signaling contribute to muscle wasting in chronic heart failure? J Appl Physiol. 2011;110: 869-70.
52. Akamizu T, Kangawa K. Therapeutic applications of ghrelin to cachexia utilizing its appetite-stimulating effect. Peptides. 2011;32: 2295-300.
53. Lund LH, Williams JJ, Freda P, et al. Ghrelin resistance occurs in severe heart failure and resolves after heart transplantation. Eur J Hear Fail. 2009;11: 789-94.
54. DeBoer MD. Ghrelin and cachexia: will treatment with GHSR-1a agonists make a difference for patients suffering from chronic wasting syndromes? Mol Cell Endocrinol. 2011;340: 97-105.
55. Xin X, Ren AJ, Zheng X, et al. Disturbance of circulating ghrelin and obestatin in chronic heart failure patients especially in those with cachexia. Peptides. 2009;30: 2281-5.
56. Miki K, Maekura R, Nagaya N, et al. Ghrelin treatment of cachectic patients with chronic obstructive pulmonary disease: a multicenter, randomized, double-blind, placebo-controlled trial. PLoS One. 2012;7: e35708.
57. Angelidis G, Valotassiou V, Georgoulias P. Current and potential roles of ghrelin in clinical practice. J Endocrinol Investig. 2010;33: 823-38.
58. Ledderose C, Kreth S, Beiras-Fernandez A. Ghrelin, a novel peptide hormone in the regulation of energy balance and cardiovascular function. Recent Pat Endocr Metab Immune Drug Discov. 2011;5: 1-6.
59. Breitbart A, Auger-Messier M, Molkentin JD, Heineke J. Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting. Am J Physiol Heart Circ Physiol. 2011;300: H1973-82.
60. Springer J, Adams V, Anker SD. Myostatin: regulator of muscle wasting in heart failure and treatment target for cardiac cachexia. Circulation. 2010;121: 354-6.
61. Heineke J, Auger-Messier M, Xu J, Sargent M, York A, Welle S, Molkentin JD. Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation. 2010;121: 419-25.
62. Murphy KT, Chee A, Gleeson BG, Naim T, Swiderski K, Koopman R, et al. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice. Am J Physiol Regul Integr Comp Physiol. 2011;301: R716-26.
63. Scarlett JM, Bowe DD, Zhu X, Batra AK, Grant WF, Marks DL. Genetic and pharmacologic blockade of central melanocortin signaling attenuates cardiac cachexia in rodent models of heart failure. J Endocrinol. 2010;206: 121-30.
64. MacDonald N. Chronic inflammatory states: their relationship to cancer prognosis and symptoms. J Roy Coll Physic Edinburgh. 2011;41: 246-53.
65. Argiles JM, Busquets S, Lopez-Soriano FJ. Anti-inflammatory therapies in cancer cachexia. Eur J Pharmacol. 2011;668: S81-6.
66. Shadfar S, Couch ME, McKinney KA, et al. Oral resveratrol therapy inhibits cancer-induced skeletal muscle and cardiac atrophy in vivo. Nutr Canc. 2011;63: 749-62.